top of page
AAO 2026: RETINA-BIOLOGICS, DIAGNOSTICS, & AI SHOWCASE
Moderators:
Robert Avery, MD, Program Committee and Aleksandra Rachitskaya, MD
Panel: Rishi P. Singh, MD, Incoming Chair, Department of Ophthalmology, Mass Eye and Ear, Mass General Brigham and Lejla Vajzovic, MD, Program Committee
Room: 255-257
Start | Company | Presenter |
|---|---|---|
2:30 PM | Conclusion | |
1:00 PM | Introduction | |
1:01 PM | Annexin Pharmaceuticals | Anna Frostegard, MD, PhD, Chief Scientific and Medical Officer |
1:06 PM | Character Biosciences | Cheng Zhang, CEO |
1:11 PM | Annexon | |
1:16 PM | Discussion | |
1:23 PM | Merck Eyebio | Tony Adamis, MD, Chief Scientific Officer |
1:28 PM | Surrozen, Inc | Daniel L. Chao, MD, PhD, VP, Head of Clinical Development |
1:33 PM | Discussion | |
1:38 PM | EyePoint, Inc | Jay S. Duker, MD, President & CEO |
1:43 PM | Ocular Therapeutix | Peter K. Kaiser, MD, Chief Development Officer |
1:48 PM | Discussion | |
1:53 PM | RetinAI US, Inc | Carlos Ciller, PhD, CEO & Co-founder |
1:58 PM | Ocular Complement Analytics | Nick Kirby, CEO |
2:03 PM | Discussion | |
2:08 PM | PulseMedica | Nir Katchinskiy, PhD, CEO |
2:13 PM | i-Lumen Scientific, Inc. | Samuel Minaker, MD, MSc, Physician Consultant |
2:18 PM | MacuTherm GmbH | Jan Tode, MD, Chief Medical Officer |
2:23 PM | Discussion |
Anchor 1
bottom of page